No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
bevacizumab + erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: A1 - Approval
|
sintilimab Sensitive: A1 - Approval
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
gefitinib Sensitive: A2 - Guideline
|
gefitinib Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
GemVin Sensitive: A2 - Guideline
|
GemVin Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
GT Sensitive: A2 - Guideline
|
GT Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
GemCarbo Sensitive: A2 - Guideline
|
GemCarbo Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
bevacizumab + atezolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
afatinib Sensitive: A2 - Guideline
|
afatinib Sensitive: A2 - Guideline
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
brigatinib Sensitive: A2 - Guideline
|
brigatinib Sensitive: A2 - Guideline
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK fusion
|
Lung Non-Squamous Non-Small Cell Cancer
|
alectinib Sensitive: A2 - Guideline
|
alectinib Sensitive: A2 - Guideline
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
EGFR L858R
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR L858R
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: A2 - Guideline
|
osimertinib Sensitive: A2 - Guideline
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
osimertinib Sensitive: B - Late Trials
|
osimertinib Sensitive: B - Late Trials
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab Sensitive: B - Late Trials
|
camrelizumab Sensitive: B - Late Trials
|
KRAS G12C
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS G12C
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab Sensitive: B - Late Trials
|
bevacizumab Sensitive: B - Late Trials
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab Sensitive: B - Late Trials
|
bevacizumab Sensitive: B - Late Trials
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR exon 19 deletion
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
EGFR L858R
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR L858R
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
crizotinib Sensitive: B - Late Trials
|
crizotinib Sensitive: B - Late Trials
|
MHC-II overexpression + PD-L1 negative
|
Lung Non-Squamous Non-Small Cell Cancer
|
MHC-II overexpression + PD-L1 negative
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
MHC-II overexpression + PD-L1 underexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
MHC-II overexpression + PD-L1 underexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: B - Late Trials
|
sintilimab Sensitive: B - Late Trials
|
ALK rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
ceritinib Sensitive: B - Late Trials
|
ceritinib Sensitive: B - Late Trials
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials
|
sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials
|
EGFR wild-type + MET overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR wild-type + MET overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
ABBV-399 Sensitive: B - Late Trials
|
ABBV-399 Sensitive: B - Late Trials
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
ensartinib Sensitive: C1 - Off-label
|
ensartinib Sensitive: C1 - Off-label
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria
|
erlotinib + ABBV-399 Sensitive: C2 – Inclusion Criteria
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria
|
bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria
|
MET overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
MET overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
ABBV-399 Sensitive: C2 – Inclusion Criteria
|
ABBV-399 Sensitive: C2 – Inclusion Criteria
|
KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
binimetinib Sensitive: C2 – Inclusion Criteria
|
binimetinib Sensitive: C2 – Inclusion Criteria
|
ALK rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
ROS1 rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
ROS1 rearrangement
|
Lung Non-Squamous Non-Small Cell Cancer
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR T790M
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
docetaxel Resistant: C3 – Early Trials
|
docetaxel Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
docetaxel Resistant: C3 – Early Trials
|
docetaxel Resistant: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
EGFR mutation + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
STK11 mutation + KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation + KEAP1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
MET positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
MET positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
durvalumab Resistant: C3 – Early Trials
|
durvalumab Resistant: C3 – Early Trials
|
EGFR expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
gefitinib Sensitive: C3 – Early Trials
|
gefitinib Sensitive: C3 – Early Trials
|
CEACAM5 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
CEACAM5 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
SAR408701 Sensitive: C3 – Early Trials
|
SAR408701 Sensitive: C3 – Early Trials
|
MGAM mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
MGAM mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
NRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
NRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
binimetinib Sensitive: C3 – Early Trials
|
binimetinib Sensitive: C3 – Early Trials
|
MAP2K1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
MAP2K1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
binimetinib Sensitive: C3 – Early Trials
|
binimetinib Sensitive: C3 – Early Trials
|
NKX2-1 expression + PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
NKX2-1 expression + PD-L1 expression
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 overexpression + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression + KRAS mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab + abemaciclib Sensitive: C3 – Early Trials
|
pembrolizumab + abemaciclib Sensitive: C3 – Early Trials
|
KRAS G12V
|
Lung Non-Squamous Non-Small Cell Cancer
|
KRAS G12V
|
Lung Non-Squamous Non-Small Cell Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
PD-L1 overexpression
|
Lung Non-Squamous Non-Small Cell Cancer
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
bevacizumab + atezolizumab Sensitive: C3 – Early Trials
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
ALK wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
ALK wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|